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Abstract The average error of pIC50 prediction reported
for 140 structures in make-and-test applications of topomer
CoMFA by four discovery organizations is 0.5. This
remarkable accuracy can be understood to result from a
topomer pose’s goal of generating ﬁeld differences only at
lattice intersections adjacent to intended structural change.
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The purpose of 3D-QSAR, as of all industrial CADD
activities, should be to provide guidance that furthers drug
discovery, usually as quantitative predictions of the bio-
logically critical properties of individual structures. Should
it not follow that a new methodology providing surpris-
ingly superior accuracy for such predictions deserves
thoughtful consideration? Particularly in view of the many
recent publications [1–8] whose very titles express sub-
stantial pessimism about many common practices and even
the fundamental principle of QSAR?
Initial outcomes of topomer CoMFA trials
Results from each of the ﬁrst seven ‘‘real world’’ make-
and-test applications of topomer CoMFA, each undoubt-
edly prospective, have all been reported as ‘‘successful’’.
However, ‘‘success’’ is a somewhat vague and subjective
outcome. As a starting criterion, there should be potency
forecasts for multiple structures from the ‘‘successful
model’’, to minimize concern about chance agreement
between prediction and result and to improve the sampling
of prediction errors. Furthermore, since the purpose of
CADD is to further drug discovery, another useful ‘‘suc-
cess’’ is to identify the structures that are most likely to
progress a current ‘‘best candidate’’ into the desired single
compound satisfying all pre-clinical requirements. How-
ever, success in the discovery project itself, generation of a
clinically promising drug candidate, remains much too
dependent on unpredictable biological outcomes to be a
more than anecdotal indicator of a ‘‘successful’’ CADD
application.
A further challenge to the broader CADD community in
assessing a claim of model ‘‘success’’ is that the structures
and biological properties, either from which the model was
derived or for which the successful predictions were made,
are almost always made conﬁdential by the guardians of
intellectual property, at least for many years and often until
any impetus sufﬁcient to publish has vanished. An alter-
native possibility, though, is to obtain the model perfor-
mance statistics themselves, in this instance for four of the
seven reported topomer CoMFA successes. Their results
appear in Table 1, where each of the four rows provides
such statistics for a model from a different discovery
organization (one biotech, two full-sized and one mid-size
pharma).
The most important results may be found in its right
hand block labeled ‘‘Make-&-Test Outcomes’’. Particularly
remarkable is the very low error of pIC50 prediction for the
four biological properties of greatest interest, slightly
greater than 0.5 whether averaged over the four distinct
models or over the total of 140 predictions. This error value
is furthermore consistent with an average pIC50 prospec-
tive prediction error of 0.6 for 148 structures predicted
from 12 independent models, as previously reported [12].
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288 structures and 16 models, including a standard devia-
tion of 0.2 among those 16 independent error values, would
seem rather substantive evidence for an extraordinary
accuracy of pIC50 predictions that topomer CoMFA
models yield, an accuracy which to the best of my
knowledge is quite unprecedented. (As one point of com-
parison, it may be recalled that the rule-of-thumb value for
the uncertainty of a measured pIC50 value is around 0.3.)
Also apparently unprecedented, though less reliably so,
is the complete absence so far of any reported ‘‘unsuc-
cessful’’ make-and-test applications of topomer CoMFA.
Although common sense dictates that this perfect ‘‘suc-
cess’’ record among the seven trials reported will not long
continue, application of probability theory to these initial
outcomes does allow some assessment of the likelihood
that a next trial will also experience ‘‘success’’. If this
likelihood of success is actually 50%, the probability of
observing four successes in the ﬁrst four trials would be
0.5^4, or 0.0625, a value whose similarity to the conven-
tional ‘‘95% conﬁdence limit’’ supports expectation of at
least a ‘‘50:50 chance’’ of success in a next trial. If the
other three ‘‘successes’’ are also accredited, then the 95%
criterion yields a lower bound to the true likelihood of
success in the next trial as about 2/3, or ‘‘2–1’’.
Performance with respect to the other above-proposed
success criterion, the counts of the predictions that ﬂagged
the structures most likely to further project goals, taken
here speciﬁcally as those having a pIC50 within (or better
than) the most desirable quartile of the pIC50 range so far
observed experimentally (in the right-most column of
Table 1), also seems acceptable. Reportedly one of these
application outcomes played a critical role in identifying a
drug candidate that is now being licensed commercially,
and two of the others signiﬁcantly inﬂuenced their projects’
future strategies.
Those statistical modelers who emphasize q
2 magni-
tudes might have been discouraged by several of the q
2
values for the model derivations themselves, in the left-
most column of Table 1. However, the values in the
adjacent SD column suggest that one cause is a modest
range of pIC50 values within several training sets, with
their pIC50 prediction accuracies nonetheless seeming
entirely satisfactory. Another factor leading to structurally
conservative predictions (those most likely to produce the
smallest errors of prediction) is sociological. The CADD
scientist may have wisely included the widest possible
structural variation in his training set, tending to lower the
q
2 of the model. However when the model is applied to
predictions in the ‘‘real world’’ context of a drug discovery
project, make-and-test recommendations will seek to
maximize the conﬁdence of a synthetic chemist, who will
usually be considering many other structural candidates for
the investment of his bench resources.
Topomer CoMFA methodology
Essentially ‘‘topomer CoMFA’’ is conventional CoMFA
using topomers as the alignments. A topomer, then, is
deﬁned [13] as a molecular fragment having a single
internal geometry or ‘‘pose’’ (conformation plus position).
The underlined words highlight the two means by which
the topomer methodologies produce high shape compati-
bilities. By deﬁnition, a molecular fragment possesses at
least one open valence, so a topomer is positioned in space,
or ‘‘rooted’’, simply by superimposing its open valence
onto a ﬁxed Cartesian vector. The single conformation of a
topomer is determined only by its own topology (‘‘2D’’
structure), and not by either direct comparison with other
structures or intramolecular energy. Yet the overall goal is
that similar fragment topologies should afford similarly
shaped topomers. Thus, topomer valence geometries are
generated by a 3D-model builder such as Concord, fol-
lowed by canonically-determined adjustments to acyclic
single bond torsions, stereochemistries, and ring ‘‘pucker-
ings’’. Topomer CoMFA simply uses topomers from the
fragmented training set as the 3D-QSAR-requisite aligned
input structures, and otherwise differs from ‘‘standard
CoMFA’’ only in its use of multiple ‘‘CoMFA columns’’,
Table 1 Outcomes of make-and-test applications of topomer CoMFA by four discovery organizations
Ref. TopCoMFA model properties Make-&-test outcomes
q
2 SD # Comp N pIC50 range # Predicted pIC50 SDEP N top pIC50
quartile
[9] 0.220 0.66 3 122 3.3–7.3 7 0.54 2
[10] 0.593 0.49 8 270 4.2–8.8 2 0.36 2
[11] 0.518 0.63 5 358 NA 44 0.69 Most
NA 0.342 0.95 7 206 4.3–8.0 87 0.48 19
Total/Average 140 0.51
See text for explanation
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123one for each set of fragments (aka ‘‘R-groups’’). Since all
of the steps in topomer generation are automatic and user
inaccessible, a topomer CoMFA prediction is almost
entirely objective, depending only on the 2D connectiv-
ity’s, user-speciﬁed fragmentations, and measured biolog-
ical potencies of the training set structures.
Reconsidering 3D-QSAR
How can topomer CoMFA’s pIC50 predictions be so
exceptionally accurate? Obviously it’s not a consequence
of allegiance to the most frequent goal when assembling
ligand descriptions for CADD analysis, maximum ﬁdelity
to any direct and presumably relevant experimental
observables. Instead, a topomer conformation may for
example even include so dismaying a physicochemical
heresy as sterically overlapping atoms. There must exist
some other causative factor for topomer CoMFA’s
remarkable performance, such as the following reconsid-
eration of 3D-QSAR now proposes.
To begin, it is recommended that the interested reader
consciously tries to set aside her or his mental models of
QSAR processes. Let us agree only that the goal in QSAR
is to seek combinations of interpretable chemical structure
descriptors whose differences afford sufﬁciently powerful
and consistent models of differences in the biological
response(s) of interest (as typically inferred from q
2)t ob e
of value in guiding decision making.
Figure 1 shows the simplest possible excerpt from a
(ﬁctitious) structure–activity table. What is the cause, the
only possible cause assuming the biological assay to be
reproducible, of the only observable response difference
within this table excerpt, between a pIC50 of 7.2 and one of
7.9? Right—it’s the replacement of –H by –F. Assuredly
the pIC50 change resulting from even such a simple
replacement of one atom by another may have been med-
iated by some profound reorganization of the geometry of
ligand-to-target bindings. Nevertheless the only cause of
such a hypothetical reorganization would remain—the
replacement of –H by –F. Admittedly such profound
reorganizations might then yield a series of pIC50
observations whose differences have no discernable or
consistent relationship to differences in their associated
structural descriptors. However that circumstance should
be revealed simply by tne lack of any model having
acceptable q
2 values.
In 3D-QSAR, the ‘‘interpretable chemical structure
descriptors’’ are of course the ligand ﬁeld values at pre-
speciﬁed grid intersections. Here follows the most critical
element of this reconsideration of 3D-QSAR. The differ-
ences among these ligand ﬁeld values arise for only two
distinct classes of reasons:
1. The direct and relatively unambiguous effects of the
intentional changes to the ligand structures themselves.
In the example of Fig. 1, the replacement of –H by –F
would have an almost negligible effect on the local
steric ﬁeld, but a substantial effect on the electrostatic
ﬁeld. Of particular importance, these direct and
unambiguous effects of an –H for –F change are
extremely local, probably insigniﬁcant at more than a
half-dozen lattice intersections (though the differential
effects of –H and –F on partial charges elsewhere in
the ligand might slightly complicate this particular
example).
2. The indirect and relatively uncertain effects of this –H
to –F difference between ligand structures on the
geometries of their binding to the target. Of particular
importance, even modest changes in the relative
geometries of binding to target will affect the ligand
ﬁeld values at dozens or even hundreds of lattice
intersections. Figure 2 shows one example of this
Fig. 1 Generation of a very simple excerpt from an imaginary QSAR
input table
Fig. 2 Example of the pose variations among structurally constant
atoms that docking of structures varying only in their terminal groups
can produce
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123phenomenon. A small combinatorial library, whose
structures differ from one another only in a few atoms
at each of their two ends, was docked into a target, the
target then being removed. Evidently the peripheral
structural differences after docking generated some-
what different locations for the actually identical
atoms of the library’s constant core structure. As
shown, even these slight differences in core atom
locations generated substantial differences in the
ligand ﬁelds at almost all the surrounding lattice
intersections, differences which even if real can at
most be the secondary causes (e.g., not the ‘‘ﬁrst
movers’’ of Aristotelian and medieval philosophy) of
the differences in the biological properties of interest.
So the reader will hopefully agree to this distinction
between two fundamental causes of differences among the
ligand ﬁeld values that are the structural descriptors in 3D-
QSAR—the primary, direct, and spatially relatively local-
ized effects of the certain changes to the ligand structures
themselves, contrasted with the secondary, relatively
uncertain, and spatially quite diffuse effects of any result-
ing changes, even if modest, to the geometries of ligand-to-
target binding.
Now, please recall a fundamental difference in the
behavior of 3D-QSAR’s foundational statistical method-
ology PLS (partial least squares) from that of the far more
familiar MLR (multiple linear regression). To detect rela-
tionships between differences in structural and biological
properties, MLR is allowed to manipulate (scale and rotate)
individual columns of structural properties, but PLS may
only manipulate (scale and rotate) the entire block of
structural properties. The adverse consequences of MLR’s
individual column manipulations—chance correlation—are
widely recognized. The adverse consequence of PLS’s
restriction to manipulation of the entire descriptor block are
not so well-known. With PLS, even a perfect correlation
with the biological property that exists with only a few
columns within the descriptor block may remain altogether
hidden, because of the ‘‘inertia’’ of the other uncorrelated
descriptors [14].
So 3D-QSAR relies on a statistical methodology which
is insensitive to correlations involving only a few
descriptor columns to analyze a descriptor matrix of ligand
ﬁeld values whose most direct, certain, and causative dif-
ferences tend to be highly localized to a few columns. To
the extent that ﬁeld variation resulting from indirect,
uncertain, and at most secondarily causative differences in
ligand-to-target binding geometries competes, the effects
of these direct, certain, and causative differences might
even remain entirely undetected.
Although the topomer alignment protocol was devel-
oped with quite different applications in mind, it turns out
that their consequences when applied to 3D-QSAR are
ligand (fragment) poses that minimize the indirect and
uncertain effects of any differences in ligand-to-target
binding geometries. Topomer alignments are intended to
generate differences in ligand ﬁeld values only where those
differences are directly caused by changes to ligand
structures. Elsewhere their goal is to produce geometrical
identities from structural identities and geometric similar-
ities from structural similarities.
Discussion and summary
The remarkably successful outcomes of the initial make-
and-test applications of topomer CoMFA models, rather
than being mysterious, thus seem a straightforward con-
sequence of how the topomer poses focus a PLS model
onto the most assuredly controllable class of ﬁeld dif-
ferences, making its proposals for structural modiﬁcation
particularly likely to be productive. While the topomer
poses also provide signiﬁcant advantages in convenience,
speed, objectivity, and functional versatility [15], any
other 3D-QSAR methodologies that restrict ﬁeld varia-
tions to the most direct effects of ligand structure varia-
tions should also tend to yield more successful
predictions. (However, to minimize the risk of chance
correlations, such restrictions should only be applied
a priori, before any PLS modeling, rather than by some
sort of iteration between PLS modeling and ﬁeld
manipulations.)
This reconsideration also may address several other
long-standing surprises about the behaviors of 3D-QSAR
and other CADD methodologies, such as:
• The superior statistical qualities of 3D-QSAR models
based on poses that superimpose presumably critical
ligand features, rather than docked conformations [16];
• The at best modest improvements in statistical quality
afforded by greater accuracies in ﬁeld calculations,
such as ﬁner grid resolution or improved atomic
charges;
• The superiority of similarities among ‘‘2D descriptors’’
(such as the Tanimoto coefﬁcients of ﬁngerprints) in
predicting biological similarities [17], compared to
similarities among 3D similarities (as PLS is probably
not the only analytical methodology that is seriously
distracted by irrelevant variation among candidate
descriptors).
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